Ilan Hadar
Chairman and CEO at Silexion Therapeutics Corp
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2024
2 years of board service in total across 1 board, counting each seat separately. Longest: Silexion Therapeutics Corp, 2 years.
Chief executive roles
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 15% of the scoring weight is on file.
- Earnings growth 15%
- 0
-55% a year in earnings per share
15% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 4, 2026 | Silexion Therapeutics Corp | Grant or award | +10,000 | — | — |
| Feb 20, 2026 | Silexion Therapeutics Corp | Grant or award | +64,350 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.